(Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for ...

FibroBiologics will present on fibroblast-based therapies for chronic diseases at a conference in Freiburg, Germany, on March 27, 2025. FibroBiologics, Inc., a biotechnology company focused on ...

Fibrosis is the body's way of patching up damage—a bit like fixing a pothole. When skin is cut or a muscle is injured, ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...

In a recent study published in Nature, researchers investigated the immune-fibroblast communication in human cardiac disease and mouse models. They found that interleukin 1 beta (IL-1β) signaling ...

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...